Profectus BioSciences, Inc., a Baltimore, MD- and Tarrytown, NY–based developer of therapeutic and preventive vaccines against infectious diseases and cancers, has received a commitment of additional funding from the PATH Malaria Vaccine Initiative (MVI).
The company intends to use the funds for proof-of-concept studies in non-human primates with proprietary, plasmid DNA (pDNA, delivered using the electroporation (EP) based TriGrid™delivery system (TriGrid) developed by Ichor Medical Systems) and recombinant vesicular stomatitis virus (rVSV) vector technologies towards the development of a preventive malaria vaccine.
Founded in 2003 and led by CSO Dr. John Eldridge, Profectus BioSciences focuses on treating and preventing viral diseases and cancers through the delivery of proprietary prime/boost vaccines and small molecules.
The company has in-licensed a group of vaccine-based technologies from Wyeth Vaccines (now part of Pfizer, Inc.) to deliver a plasmid DNA (pDNA) vaccine to “prime” the immune system, followed by a “boost” using a recombinant vesicular stomatitis virus (rVSV) vector. In addition to malaria, current disease and virus targets include human immunodeficiency virus (HIV), hepatitis C virus (HCV), human papilloma virus (HPV), herpes simplex virus type 2 (HSV-2) and Ebola/Marburg viruses.